Research analysts at StockNews.com assumed coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) in a research note issued on Saturday. The firm set a "hold" rating on the stock.
Separately, HC Wainwright raised shares of Diffusion Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $9.50 price objective on the stock in a research report on Tuesday, August 16th.
Get Diffusion Pharmaceuticals alerts:Diffusion Pharmaceuticals Stock Down 0.6 %
DFFN opened at $5.35 on Friday. The stock has a market cap of $10.91 million, a PE ratio of -0.44 and a beta of 1.53. The company has a fifty day moving average of $6.47 and a 200-day moving average of $10.94. Diffusion Pharmaceuticals has a twelve month low of $5.10 and a twelve month high of $26.18.
Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($2.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.77) by ($0.29). Sell-side analysts anticipate that Diffusion Pharmaceuticals will post -8.43 EPS for the current fiscal year.Hedge Funds Weigh In On Diffusion Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of DFFN. JPMorgan Chase & Co. purchased a new stake in shares of Diffusion Pharmaceuticals in the 1st quarter valued at $106,000. Renaissance Technologies LLC raised its holdings in Diffusion Pharmaceuticals by 8.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company's stock valued at $331,000 after buying an additional 101,100 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in Diffusion Pharmaceuticals during the 2nd quarter valued at $71,000. Hedge funds and other institutional investors own 10.25% of the company's stock.
About Diffusion Pharmaceuticals
(Get Rating)
Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc was founded in 2001 and is based in Charlottesville, Virginia.
Featured Articles
- Get a free copy of the StockNews.com research report on Diffusion Pharmaceuticals (DFFN)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.